Linscomb & Williams Inc. Sells 3,846 Shares of Amgen Inc. (NASDAQ:AMGN)

Linscomb & Williams Inc. reduced its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 9.8% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 35,306 shares of the medical research company’s stock after selling 3,846 shares during the quarter. Linscomb & Williams Inc.’s holdings in Amgen were worth $10,169,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in AMGN. BOK Financial Private Wealth Inc. acquired a new stake in Amgen during the 4th quarter worth approximately $29,000. Providence Capital Advisors LLC acquired a new stake in shares of Amgen during the third quarter worth $30,000. Planned Solutions Inc. bought a new stake in shares of Amgen in the fourth quarter valued at about $30,000. Delos Wealth Advisors LLC grew its stake in shares of Amgen by 2,500.0% in the fourth quarter. Delos Wealth Advisors LLC now owns 104 shares of the medical research company’s stock valued at $30,000 after acquiring an additional 100 shares in the last quarter. Finally, Hartford Financial Management Inc. increased its position in Amgen by 56.9% during the fourth quarter. Hartford Financial Management Inc. now owns 113 shares of the medical research company’s stock worth $33,000 after acquiring an additional 41 shares during the period. 76.50% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages recently issued reports on AMGN. BMO Capital Markets increased their price target on Amgen from $336.00 to $355.00 and gave the stock an “outperform” rating in a research report on Friday, May 3rd. Oppenheimer restated an “outperform” rating and issued a $350.00 price target on shares of Amgen in a research report on Thursday, February 1st. William Blair raised shares of Amgen from a “market perform” rating to an “outperform” rating in a research report on Friday, May 3rd. Barclays upgraded shares of Amgen from an “underweight” rating to an “equal weight” rating and increased their price objective for the stock from $230.00 to $300.00 in a research note on Friday, May 3rd. Finally, UBS Group boosted their target price on shares of Amgen from $284.00 to $307.00 and gave the company a “neutral” rating in a research report on Friday, May 3rd. Ten analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $305.65.

Amgen Trading Down 0.2 %

NASDAQ AMGN traded down $0.66 during trading hours on Friday, hitting $305.84. 2,425,864 shares of the company’s stock were exchanged, compared to its average volume of 2,869,476. Amgen Inc. has a 1-year low of $211.71 and a 1-year high of $329.72. The company has a current ratio of 1.42, a quick ratio of 0.98 and a debt-to-equity ratio of 11.96. The stock has a 50-day simple moving average of $285.02 and a 200 day simple moving average of $285.61. The firm has a market cap of $164.06 billion, a price-to-earnings ratio of 43.69, a PEG ratio of 2.76 and a beta of 0.60.

Amgen (NASDAQ:AMGN) last issued its earnings results on Thursday, May 2nd. The medical research company reported $3.96 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.76 by $0.20. Amgen had a net margin of 12.74% and a return on equity of 156.21%. The business had revenue of $7.45 billion for the quarter, compared to analyst estimates of $7.45 billion. During the same period in the prior year, the firm earned $3.98 earnings per share. Amgen’s revenue was up 22.0% on a year-over-year basis. On average, equities analysts forecast that Amgen Inc. will post 19.47 EPS for the current fiscal year.

Amgen Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 7th. Shareholders of record on Friday, May 17th will be paid a dividend of $2.25 per share. The ex-dividend date is Thursday, May 16th. This represents a $9.00 dividend on an annualized basis and a yield of 2.94%. Amgen’s dividend payout ratio (DPR) is presently 128.57%.

Insider Buying and Selling at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 2,117 shares of Amgen stock in a transaction dated Friday, May 3rd. The stock was sold at an average price of $313.09, for a total transaction of $662,811.53. Following the completion of the transaction, the senior vice president now owns 9,883 shares in the company, valued at approximately $3,094,268.47. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 0.69% of the company’s stock.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.